Literature DB >> 17408073

Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire.

Marianna P Yaneva1, Maria A Semerdjieva.   

Abstract

UNLABELLED: Assessment of quality of life (QOL) is of crucial importance when assigning palliative radiotherapy of brain metastases in cancer patients. AIM: To investigate the influence of whole brain radiotherapy on brain symptoms in patients with cerebral metastases; to evaluate their quality of life before and after radiation therapy using the EORTC-QOL-C30 questionnaire, as well as its influence on patients' survival. PATIENTS AND METHODS: Sixty-five patients with various locations of the primary tumor and brain metastases were included in this study. All of them underwent radiotherapy with cobalt unit. The realized dose of the whole brain was above 30 Gy: 10 x 3 Gy or 15 x 2 Gy. The patients filled in the EORTC-QOL-C30 questionnaire before radiation, at the end of the radiotherapeutic course and a month after it. Clinical characteristics of patients before and after radiotherapy were compared and assessed. All patients were treated with radiotherapy and concurrent corticosteroid treatment.
RESULTS: The mean age of the patients was 53 +/- 7.8 years and the median survival was 6.6 months for lung cancer patients and 9.8 months for breast cancer patients. Each EORTC-QOL-C30 questionnaire assessed the patients in three main aspects: functional aspects, general symptoms and global health. Improvement was reported (p < 0.001) for functional indicators and health related quality of life (HRQOL). Several symptoms did not change significantly--financial difficulties, dyspnea and diarrhea.
CONCLUSIONS: Whole brain radiation of cancer patients with cerebral metastases is very well tolerated. Side effects are frequently met and can be compensated by applying steroids. The assessment of quality of life gives information on patients' improvement which is more substantial in functioning, symptoms and global health. This study is a precondition for future investigations of the effect of whole brain radiation on cancer patients' quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 17408073

Source DB:  PubMed          Journal:  Folia Med (Plovdiv)        ISSN: 0204-8043


  6 in total

1.  Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy.

Authors:  Erin Wong; Liying Zhang; Leigha Rowbottom; Nicholas Chiu; Leonard Chiu; Rachel McDonald; May Tsao; Elizabeth Barnes; Cyril Danjoux; Edward Chow
Journal:  Support Care Cancer       Date:  2016-06-29       Impact factor: 3.603

2.  EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy.

Authors:  Amanda Caissie; Shaelyn Culleton; Janet Nguyen; Liying Zhang; Liang Zeng; Lori Holden; Kristopher Dennis; Esther Chan; Florencia Jon; May Tsao; Cyril Danjoux; Arjun Sahgal; Elizabeth Barnes; Kaitlin Koo; Edward Chow
Journal:  Support Care Cancer       Date:  2011-05-03       Impact factor: 3.603

Review 3.  Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Authors:  Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

4.  Quality of life and radiotherapy in brain metastasis patients.

Authors:  Gonçalo Fernandez; Rute Pocinho; Catarina Travancinha; Eduardo Netto; Margarida Roldão
Journal:  Rep Pract Oncol Radiother       Date:  2012-09-05

5.  Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases.

Authors:  Patricia Suteu; Zsolt Fekete; Nicolae Todor; Viorica Nagy
Journal:  Med Pharm Rep       Date:  2019-01-15

6.  Quality of life in brain metastases radiation trials: a literature review.

Authors:  J Wong; A Hird; A Kirou-Mauro; J Napolskikh; E Chow
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.